Oxaliplatin
Product Images NDC 47335-178

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 47335-178). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

An illustration labeled Figure 1 showing a two-day treatment cycle involving oxaliplatin injection 85 mg/m2, leucovorin 200 mg/m2, and 5-FU bolus and infusion doses. The diagram details the timing and sequence of administration over 48 hours with specific infusion durations on Day 1 and Day 2.*

FDA Label Image

Figure-2 (Figure 2)

A Kaplan-Meier survival curve chart illustrating Disease-Free Survival (DFS) probability over 72 months comparing two treatment arms, FOLFOX4 and LV5FU2. The chart includes number of events, hazard ratio with confidence interval, p-value from stratified logrank test, and counts of patients at risk over time for each treatment group.*

FDA Label Image

Figure-3 (Figure 3)

A Kaplan-Meier curve chart showing Disease-Free Survival (DFS) probability over 72 months in Stage III patients, comparing two treatment arms: FOLFOX4 (solid line) and LV5FU2 (dashed line). The chart includes a hazard ratio of 0.78 with a 95% confidence interval and a logrank test p-value of 0.005. The data cutoff is June 1, 2006.*

FDA Label Image

Figure-4 (Figure 4)

A Kaplan-Meier survival curve chart comparing overall survival of patients treated with Oxaliplatin for Injection combined with 5-FU/LV, Oxaliplatin for Injection combined with Irinotecan, and Irinotecan combined with 5-FU/LV. The y-axis shows percent of patients surviving from 0 to 100%, and the x-axis shows months from 0 to 24. Median survival times are listed as 19.4 months, 17.6 months, and 14.6 months respectively, with a log rank test p-value less than 0.0001 indicating statistical significance.*

FDA Label Image

Label-100mg (Label 100mg)

Label for Oxaliplatin For Injection, USP 100 mg, sterile lyophilized powder for intravenous use only. Distributed and manufactured by Sun Pharmaceutical Industries, Inc. The label includes storage instructions, reconstitution guidelines, and a barcode. It specifies the vial is single use and preservative-free, with warnings against use with sodium chloride/chloride solutions.*

FDA Label Image

Label-50mg (Label 50mg)

Label for Oxaliplatin For Injection, USP 50 mg sterile lyophilized powder, a cytotoxic agent for intravenous use only, single-use vial. Distributed by Sun Pharmaceutical Industries, Inc. and manufactured by Sun Pharmaceutical Ind. Ltd. Storage instructions and usage warnings included. Barcode present on the right side with NDC 47335-176-40.*

FDA Label Image

Chemical Structure (Oxaliplatin Struct)

Chemical structure of Oxaliplatin showing the platinum (Pt) center bound to a bidentate 1,2-diaminocyclohexane ligand and oxalate groups.*

FDA Label Image

Showbox-100mg (Showbox 100mg)

Oxaliplatin For Injection, USP 100 mg packaging label from Sun Pharmaceutical Industries, Inc. The label indicates it is a cytotoxic agent for intravenous use only in a single-use vial. The product is sterile lyophilized powder, preservative free, and must be reconstituted and diluted before use. It also advises not to reconstitute with sodium chloride or chloride-containing solutions. The label includes storage instructions, inactive ingredients, manufacturer details, and a barcode.*

FDA Label Image

Showbox-50mg (Showbox 50mg)

Oxaliplatin For Injection, USP 50 mg vial label from Sun Pharmaceutical Industries, Inc. The label states this is a cytotoxic agent for intravenous use only, single use vial. It contains sterile lyophilized powder, preservative free, requiring reconstitution and dilution before use. The label includes storage and reconstitution instructions, inactive ingredient lactose monohydrate, and distribution and manufacturing details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.